Drug Trial Radar · NCT06572228
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Actual
Start
Aug 26, 2024
Primary completion
Apr 24, 2027
Study completion Apr 24, 2027
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Aug 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication. The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medication. The type of asthma medication that will be used is a combination inhaled corticosteroid and long-acting beta-agonist (referred to as an ICS/LABA). Some patients may also receive an additional asthma medication called a long-acting muscarinic antagonist (referred to as a LAMA) if they are already receiving a LAMA. The study is also looking at: • What side effects may happen from taking dupilumab
Conditions
- Asthma
Interventions
dupilumabDrug
Administered by subcutaneous (SC) injection
Matching PlaceboDrug
Administered by SC injection
ICS/LABADrug
Administered at a blinded dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized severe asthma exacerbation rateTime frame: Baseline through Week 52
Locations
77 sites in 6 countries. Site status is shown where the registry gives one.
Kern Research, Inc
Bakersfield, California
Modena Allergy & Asthma, Inc.
La Jolla, California
Antelope Valley Clinical Trials
Lancaster, California
Ark Clinical Research, LLC
Long Beach, California
Newport Native Md, Inc.
Newport Beach, California
Childrens Hospital of Orange County Main Campus
Orange, California
Raffi Tachdjian MD, Inc.
Santa Monica, California
Bensch Clinical Research
Stockton, California
Integrated Research of Inland, Inc.
Upland, California
Allianz Research Institute
Westminster, California
National Jewish Health
Denver, Colorado
St Francis Medical Institute
Clearwater, Florida
Florida Lung, Asthma and Sleep Specialists (FLASS) - Celebration
Kissimmee, Florida
Clinical Site Partners, LLC DBA Flourish Research
Winter Park, Florida
Treasure Valley Medical Research
Boise, Idaho
Sneeze Wheeze and Itch Associates
Normal, Illinois
Asthma and Allergy Center of Chicago
River Forest, Illinois
Endeavor Health, Skokie Campus
Skokie, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Bluegrass Allergy Research
Lexington, Kentucky
Family Allergy and Asthma Research Institute
Louisville, Kentucky
Allergy & Asthma Specialists, P.S.C.
Owensboro, Kentucky
Paul A. Shapero, M.D.
Bangor, Maine
Massachusetts General Hospital
Boston, Massachusetts
Michigan Medicine
Ann Arbor, Michigan
Henry Ford Hospital
Detroit, Michigan
Clinical Research Institute, Inc.
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
Montana Medical Research
Missoula, Montana
The Asthma and Allergy Center
Bellevue, Nebraska
Henderson Clinical Trials
Henderson, Nevada
Certified Research Associates
Cortland, New York
New York Medical College
Hawthorne, New York
Northwell Health at ENT & Allergy Associates
New York, New York
Rochester Regional Health - Alexander Park - Allergy, Immunology & Rheumatology
Rochester, New York
Cincinnati Childrens Hospital and Medical Center
Cincinnati, Ohio
Allergy Asthma and Clinical Research Center
Oklahoma City, Oklahoma
Clinical Research Associates of Central PA
DuBois, Pennsylvania
University of Pittsburgh Asthma and Environmental Health Lung Institute
Pittsburgh, Pennsylvania
Pulmonology Associates Inc.
Wynnewood, Pennsylvania
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.